Merolin 5mg Tablet

Dosage & Administration

Normally, the initial dose for adults is 5 mg of Mirogabalin given orally twice daily, and then the dose is gradually increased by 5 mg at an interval of at least a week to 15 mg, given orally twice daily. A dose may be adjusted appropriately between 10 mg and 15 mg depending on ages and symptoms, given twice daily. * Take medicine as per doctor's advice

Interaction

Mirogabalin does not induce or inhibit cytochrome P450 isoenzymes. Coadministration of Mirogabalin with Cimetidine or Probenecid may raise the Mirogabalin plasma concentration. Importantly, if mirogabalin is taken with alcohol or lorazepam, the depressive effects on the CNS may be potentiated.

Contraindications

Mirogabalin is contraindicated in: patients with hypersensitive to Mirogabalin. patients with mild to moderate Hepatic & Renal impairment.

Side Effects

The most reported adverse reactions include somnolence, dizziness, edema and weight gain. The symptoms described below are rarely seen as initial symptoms of the adverse reactions indicated in brackets. If any of these symptoms occur, stop taking this medicine and see your doctor immediately. Light headedness, state close to sleep with impaired consciousness, loss of consciousness (dizziness, somnolence, unconsciousness). General malaise, loss of appetite, nausea, vomiting, jaundice (liver dysfunction).

Precautions & Warnings

This medicine may cause dizziness, somnolence, or loss of consciousness. Avoid operating dangerous machinery, such as driving a car. Especially for elderly patients, careful attention should be taken. This medicine may cause weight gain. This medicine may cause blurred vision and double vision.

Storage Conditions

Store at below 30°C and dry place, away from light and moisture. Keep out of the reach of children.

Brief Description

Indications

Mirogabalin Besylate is indicated for the treatment of- Neuropathic Pain, Diabetic peripheral neuropathic pain (DPNP), Postherpetic neuralgia (PHN), Peripheral neuropathic pain (PNP)

Pharmacology

Mirogabalin has selective and potent binding affinities for human α2δ subunits of VGCCs, which reduce calcium (Ca2+) influx and neurotransmission in DRG, inhibiting neurotransmitter release in pre-synaptic neuron endings.